Rituximab rescues severe PR3-ANCA pulmonary-renal syndrome when standard drugs fail
A case report details how rituximab controlled severe PR3-ANCA pulmonary-renal syndrome in a dialysis-dependent patient after conventional induction therapy failed.
A case report details how rituximab controlled severe PR3-ANCA pulmonary-renal syndrome in a dialysis-dependent patient after conventional induction therapy failed.
A new review maps where the off-label anti-CD20 antibody rituximab fits in the treatment of systemic lupus erythematosus, from refractory ...
A cross-sectional study shows that ocrelizumab selectively contracts EBV-specific CD4 T-cell immunity in multiple sclerosis while preserving antiviral defenses against ...
A retrospective real-world study from Milan's San Raffaele institute compares ocrelizumab and ofatumumab as successor therapies for multiple sclerosis patients ...
A two-year real-world study found that ofatumumab sustained B-cell depletion in multiple sclerosis patients while producing significant increases in broad ...
A new case series and literature review report that ocrelizumab, a leading multiple sclerosis therapy, is associated with a rare ...
A phase III trial of obinutuzumab β shows striking efficacy in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder, deepening questions about which ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine